This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
View your own country’s website
Close

A dedicated women's health company

Close

Understanding contraceptive options to meet your needs

Close

Supporting you through the menopause

Close

Helping you thrive through osteoporosis

Close

Helping you through the challenges of fertility

Close

Theramex News

Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Get in touch

Close

Careers

Theramex news

Stay up to date with the latest news from Theramex.

Reset all filters

20 December 2024

Theramex Announces European Commission Approval for Yselty®▼ (linzagolix) for Symptomatic Treatment of Endometriosis in Women with a History of Previous Medical or Surgical Treatment for their Endometriosis

Read more

17 December 2024

Theramex’s Sustainability Report 2023

Read more

13 September 2024

Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

Read more

11 December 2023

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris. 

Read more

1 December 2023

Theramex Office Opening and Panel Discussion

Read more

2 October 2023

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

Read more

Load more

Read more about Theramex